Overview of the Hatch-Waxman Act and its impact on the drug development process.
Explore this paper's citation graph
Summary
The article provides a timetable to compare the drug discovery and development, patent protection, and generic competition processes that the Act affects and some insight into the Act’s underlying assumptions, with the help of some graphics.
- Type
- article
- Published
- 1999-01-01
- Cited by
- 88
- References
- 0
- OpenAlex
- https://openalex.org/W20211414
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:36107034
Keywords
Drug development, Business, Drug, Process (computing), Drug approval
References
No references recorded for this paper.
Cited by
- The market for follow-on biologics: how will it evolve?
- Essays on competition in the pharmaceutical industry
- An empirical study on the role of patents in fostering local pharmaceutical innovation in China
- The Protection of Pharmaceutical Patents and Data under TRIPS and US-Jordan FTA: Exploring the Limits of Obligations and Flexibilities: A Study of the Impacts on the Pharmaceutical Sector in Jordan
- Pharmaceutical patents and generic entry competition: the role of marketing exclusivity
- Review on Development of Orphan Drug for Rare Disease
- Protection of fixed-dose combination drugs by patent term extension
- I'm Still Your Baby: Canada's Continuing Support of U.S. Linkage Regulations for Pharmaceuticals
- Essays on Intellectual Property
- Starving (or Fattening) the Golden Goose?: Generic Entry and the Incentives for Early-Stage Pharmaceutical Innovation
- Regulation and adoption dynamics of pharmaceutical technologies : evidence from the OECD, 1999-2008
- Rx-to-OTC Switch: Changes in Physician and Patient Behavior
- Biosimilars: are they ready for primetime in the United States?
- Current challenges facing the determination of product bioequivalence in veterinary medicine.
- The challenge of follow-on biologics for treatment of multiple sclerosis
- The effect of mandatory generic substitution on the safety of alendronate and patients’ adherence
- Pricing and Reimbursement in U.S. Pharmaceutical Markets
- Drug Repurposing from an Academic Perspective
- India, TRIPS-plus free trade agreements and the future of access to essential medicines
- Do firms underinvest in long-term research? Evidence from cancer clinical trials
Related papers
- Drug Development: Stages of Drug Development
- Strategic proposals to avoid toxic drug interactions during new drug development: molecular toxicology proposals.
- An Overview of How the Food and Drug Administration Regulates New Drug Development in the United States
- TO THE QUESTION OF THE ROLE AND SIGNIFICANCE OF CONTROLLING IN THE PROCESS OF IMPLEMENTING THE PROGRAMS OF STRATEGIC DEVELOPMENT OF MUNICIPALITY
- Preclinical drug development in the antiepileptic drug development program. A cooperative effort of government and industry.
- E-process Enhancing Strategy Executive Ability